Danielle Bucco

Recommended treatment regimens for patients with renal cell carcinoma (RCC) continue to change as novel therapies and combinations are approved by the FDA.

Nadine M. Tung, MD, discussed the role of PARP inhibitors for patients with BRCA-positive breast cancer and the importance of genetic testing.

Mark J. Mann, MD, discusses the developing treatment landscape for patients with nonmetastatic castration-resistant prostate cancer.

Mothaffar Fahed Rimawi, MD, explains the importance of targeting treatments for patients with low levels of HER2 protein based on their genetic mutations, and the possible use of immunotherapy for these patients.

“Immunotherapy is a new option for patients and is well established,” said George R. Blumenschein, MD. “We are refining how we use it. There will be a number of additional refinements as we have the new data that will be coming forward in the next few months.”

“Are there ways that we can optimize the cure rates with HIFU? When are people recurring? What are we missing when they recur? What are the true rates of complications? We do not know the answer to most of these questions,” says Jonathan Warner, MD.

Francisco J. Esteva, M.D., Ph.D. discussed genomic testing at the 16th Annual International Congress on the Future of Breast Cancer® (East).

A patient can experience less pain, a quicker healing time and potentially more normal kidney function, due to the minimally invasive aspect of robotic surgery, according to Ketan K. Badani, M.D.

Breast cancer expert Joyce O'Shaughnessy, MD, discusses the current treatments for metastatic triple negative breast cancer (TNBC) as well as potential options in the future.

A recent analysis showed that many women within the recommended age for routine screening are not up to date on Pap tests.

John E. Mullinax, M.D., discusses a chemotherapy strategy, isolated limb infusion, that may be able to save the limbs of some patients with sarcoma.

Expert Adam M. Brufsky, MD, PhD, discusses the considerations for bone-targeted agents denosumab and zoledronic acid (Zometa) in patients with breast cancer.

A multidisciplinary team went to Botswana to bring more effective treatment to patients with cervical cancer.

Breast cancer expert Carey Anders discusses treatment for breast cancer patients with brain metastases.